Elexacaftor / tezacaftor / ivacaftor · Trikafta
Small molecule
Evidence outlook
Approved: Cystic Fibrosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (1)
- Cystic fibrosis (with ivacaftor), at least one non-Class I CFTR mutation; sold in the EU as Kaftrio
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03525444 NCT03525444 · Cystic Fibrosis Trial 1 in the TRIKAFTA label was a 24-week, randomized, double-blind, placebo-controlled Phase 3 trial in 405 people aged 12 and older with one F508del variant and a minimal function variant. The single primary endpoint was the absolute change in percent predicted FEV1 at Week 4. TRIKAFTA improved it by 13.8 percentage points more than placebo (95% CI 12.1 to 15.4, P<0.0001), so the primary endpoint was met. Sources: the FDA label (TRIKAFTA) and the CT.gov posted results. Registry: NCT03525444 | 3 | Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) (From Baseline at Week 4) 2019-04-24 | Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results). | Reliable signal | link ↗ |
View 2 more trials
NCT03525548 NCT03525548 · Cystic Fibrosis Trial 2 in the TRIKAFTA label was a 4-week, randomized, double-blind, active-controlled Phase 3 trial in 113 people aged 12 and older who were homozygous for F508del, comparing TRIKAFTA with tezacaftor/ivacaftor after an open-label tezacaftor/ivacaftor run-in. The single primary endpoint was the absolute change in percent predicted FEV1 at Week 4. TRIKAFTA improved it by 10.0 percentage points more than tezacaftor/ivacaftor (95% CI 7.4 to 12.6, P<0.0001), so the primary endpoint was met. Sources: the FDA label (TRIKAFTA) and the CT.gov posted results. Registry: NCT03525548 | 3 | Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) (From Baseline at Week 4) 2018-12-28 | Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results). | Reliable signal | link ↗ |
NCT05274269 NCT05274269 · Cystic Fibrosis Trial 5 in the TRIKAFTA label was a 24-week, randomized, double-blind, placebo-controlled Phase 3 trial in 307 people aged 6 and older with cystic fibrosis and a responsive variant other than F508del. The single primary endpoint was the absolute change in percent predicted FEV1 through Week 24. TRIKAFTA improved it by 9.2 percentage points more than placebo (95% CI 7.2 to 11.3, P<0.0001), so the primary endpoint was met. Sources: the FDA label (TRIKAFTA) and the CT.gov posted results. Registry: NCT05274269 | 3 | Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) (From Baseline Through Week 24) 2023-07-05 | Absolute change in ppFEV1 from baseline through Week 24: +8.9 with TRIKAFTA vs -0.4 with placebo; treatment difference 9.2 percentage points (95% CI 7.2 to 11.3), P<0.0001 (TRIKAFTA label section 14.2; CT.gov posted results). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (2)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (2)
What this study did
What this study did
Competitive landscape
5 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Cystic Fibrosis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Elexacaftor / Tezacaftor / Ivacaftor (Trikafta): this drug | Approved | Small molecule | CFTR | Reliable signal | NCT03525444: Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results). NCT03525548: Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results). | |
| Ivacaftor (Kalydeco) | Approved | Small molecule | CFTR | Partial signal | NCT00909727: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1) NCT00909532: Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7) | |
| Lumacaftor (Orkambi) | Approved | Small molecule | CFTR | Reliable signal | No reviewed efficacy summary in this indication | |
| Tezacaftor / Ivacaftor (Symdeko) | Approved | Small molecule | CFTR | not yet graded | No reviewed efficacy summary in this indication | |
| Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek) | Approved | Small molecule | CFTR, CFTR | Reliable signal | No reviewed efficacy summary in this indication | |
| KB407 | Phase 1 | Gene therapy / editing | CFTR (gene replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| VX-828 | Phase 1 | Small molecule | CFTR | not yet graded | No reviewed efficacy summary in this indication | |
| Luvomeran | Discontinued | RNA / oligonucleotide | CFTR (mRNA replacement) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Trikafta (Elexacaftor / tezacaftor / ivacaftor) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
April 2027 (1)
What to watch
July 2027 (1)
What to watch
September 2027 (1)
What to watch
2029 (1)
July 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent